These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 31098724)
1. Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab? Novotna K; Rusz J; Kubala Havrdova E; Lizrova Preiningerova J J Neural Transm (Vienna); 2019 Jun; 126(6):731-737. PubMed ID: 31098724 [TBL] [Abstract][Full Text] [Related]
2. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM. Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355 [TBL] [Abstract][Full Text] [Related]
4. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D; Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067 [TBL] [Abstract][Full Text] [Related]
6. Utility of the Six-Spot Step Test as a Measure of Walking Performance in Ambulatory Individuals With Multiple Sclerosis. Fritz NE; Jiang A; Keller J; Zackowski KM Arch Phys Med Rehabil; 2016 Apr; 97(4):507-512. PubMed ID: 26577146 [TBL] [Abstract][Full Text] [Related]
7. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197 [TBL] [Abstract][Full Text] [Related]
8. Further validation of multiple sclerosis walking scale-12 scores based on spatiotemporal gait parameters. Pilutti LA; Dlugonski D; Sandroff BM; Suh Y; Pula JH; Sosnoff JJ; Motl RW Arch Phys Med Rehabil; 2013 Mar; 94(3):575-8. PubMed ID: 22960049 [TBL] [Abstract][Full Text] [Related]
9. Maximum walking speed in multiple sclerosis assessed with visual perceptive computing. Grobelny A; Behrens JR; Mertens S; Otte K; Mansow-Model S; Krüger T; Gusho E; Bellmann-Strobl J; Paul F; Brandt AU; Schmitz-Hübsch T PLoS One; 2017; 12(12):e0189281. PubMed ID: 29244874 [TBL] [Abstract][Full Text] [Related]
10. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044 [TBL] [Abstract][Full Text] [Related]
11. End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines? Cathérine D; Annelien P; Anne S; Luc A; Liesbeth VH; Gerlo S; Guy L Mult Scler Relat Disord; 2020 Jun; 41():102020. PubMed ID: 32146430 [TBL] [Abstract][Full Text] [Related]
13. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making. van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213 [TBL] [Abstract][Full Text] [Related]
14. The relationship between fear of falling to spatiotemporal gait parameters measured by an instrumented treadmill in people with multiple sclerosis. Kalron A; Achiron A Gait Posture; 2014 Feb; 39(2):739-44. PubMed ID: 24200869 [TBL] [Abstract][Full Text] [Related]
15. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. Cadavid D; Jurgensen S; Lee S PLoS One; 2013; 8(1):e53297. PubMed ID: 23308186 [TBL] [Abstract][Full Text] [Related]
16. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores. Motl RW; Cadavid D; Sandroff BM; Pilutti LA; Pula JH; Benedict RH J Neurol Sci; 2013 Dec; 335(1-2):169-73. PubMed ID: 24104065 [TBL] [Abstract][Full Text] [Related]
17. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS. Hobart J; Blight AR; Goodman A; Lynn F; Putzki N Neurology; 2013 Apr; 80(16):1509-17. PubMed ID: 23535489 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal measurement invariance of the Multiple Sclerosis Walking Scale-12. Motl RW; McAuley E; Mullen S J Neurol Sci; 2011 Jun; 305(1-2):75-9. PubMed ID: 21474149 [TBL] [Abstract][Full Text] [Related]
19. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria? Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976 [TBL] [Abstract][Full Text] [Related]